Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
Open Access
- 15 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 13 (1), 1-12
- https://doi.org/10.1186/s13045-020-00866-6
Abstract
Rearranged during transfection (RET) has been proven to be a tumorigenic target in non-small cell lung cancers (NSCLCs). In RET-rearranged NSCLCs, molecular features and their impact on prognosis were not well illustrated, and the activity of mainstay therapeutics has not currently been well compared. Patients diagnosed with NSCLCs with RET rearrangements were analyzed for concomitant mutations, tumor mutation burden (TMB), PD-L1 expression, T cell receptor repertoire and clinical outcomes with chemotherapy, immune checkpoint inhibitors (ICIs), and multikinase inhibitors (MKIs). Among 129 patients with RET-rearranged NSCLC who were analyzed, 41.1% (53/129) had co-occurring genetic alterations by next-generation sequencing, and concomitant TP53 mutation appeared most frequently (20/53, 37.7%). Patients with concurrent TP53 mutation (n = 15) had shorter overall survival than those without (n = 30; median, 18.4 months [95% CI, 8.6–39.1] vs 24.8 months [95% CI, 11.7–52.8]; P < 0.05). Patients with lower peripheral blood TCR diversity (n = 5) had superior overall survival compared with those with higher diversity (n = 6; median, 18.4 months [95% CI, 16.9–19.9] vs 4.8 months [95% CI, 4.5–5.3]; P = 0.035). An association with overall survival was not observed for PD-L1 expression nor for tumor mutation burden level. Median progression-free survival was not significantly different across chemotherapy, ICIs, and MKIs (median, 3.5 vs 2.5 vs 3.8 months). For patients treated with ICIs, the disease control rate was 60% (6/10) and the objective response rate was 20% (2/10). RET-rearranged lung cancers can be heterogeneous in terms of concomitant genetic alterations. Patients with concurrent TP53 mutation or high peripheral blood TCR repertoire diversity have relatively inferior overall survival in this series. Outcomes with traditional systemic therapies in general are suboptimal.Keywords
Funding Information
- National Key Technology R&D Program of the Ministry of Science and Technology of China: Prevention and Control of Major Non-communicable Diseases (Grant No. 2016YFC 1303304/1303300)
This publication has 42 references indexed in Scilit:
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against MelanomaCancer Immunology Research, 2019
- Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinomaInternational Journal of Cancer, 2018
- Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerAnnals of Oncology, 2018
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryJournal of Clinical Oncology, 2017
- Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinomaLung Cancer, 2016
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanomaJournal for ImmunoTherapy of Cancer, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysisBritish Journal of Cancer, 2014
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET FusionsThe Oncologist, 2013
- When mutants gain new powers: news from the mutant p53 fieldNature Reviews Cancer, 2009